236 related articles for article (PubMed ID: 28597467)
1. Development of indicators for evaluating the appropriate use of triazoles for invasive fungal disease: A Delphi panel survey.
Dong WH; Zhang GZ; Li JX; Wang Y; Wang TT; Dong YL
J Clin Pharm Ther; 2017 Dec; 42(6):720-732. PubMed ID: 28597467
[TBL] [Abstract][Full Text] [Related]
2. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.
McCreary EK; Davis MR; Narayanan N; Andes DR; Cattaneo D; Christian R; Lewis RE; Watt KM; Wiederhold NP; Johnson MD
Pharmacotherapy; 2023 Oct; 43(10):1043-1050. PubMed ID: 37459118
[TBL] [Abstract][Full Text] [Related]
3. Triazole antifungals: a review.
Peyton LR; Gallagher S; Hashemzadeh M
Drugs Today (Barc); 2015 Dec; 51(12):705-18. PubMed ID: 26798851
[TBL] [Abstract][Full Text] [Related]
4. Triazole antifungal agents in invasive fungal infections: a comparative review.
Lass-Flörl C
Drugs; 2011 Dec; 71(18):2405-19. PubMed ID: 22141384
[TBL] [Abstract][Full Text] [Related]
5. Safety of triazole antifungal drugs in patients with cancer.
Cronin S; Chandrasekar PH
J Antimicrob Chemother; 2010 Mar; 65(3):410-6. PubMed ID: 20035021
[TBL] [Abstract][Full Text] [Related]
6. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
7. Update on azole antifungals.
Zonios DI; Bennett JE
Semin Respir Crit Care Med; 2008 Apr; 29(2):198-210. PubMed ID: 18366001
[TBL] [Abstract][Full Text] [Related]
8. Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome.
Ceesay MM; Couchman L; Smith M; Wade J; Flanagan RJ; Pagliuca A
Med Mycol; 2016 Oct; 54(7):691-8. PubMed ID: 27161786
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
10. Why do lung transplant patients discontinue triazole prophylaxis?
Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
[TBL] [Abstract][Full Text] [Related]
11. New antifungal agents.
Gupta AK; Tomas E
Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
[TBL] [Abstract][Full Text] [Related]
12. [Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].
Scodavolpe S; Quaranta S; Lacarelle B; Solas C
Ann Biol Clin (Paris); 2014; 72(4):391-404. PubMed ID: 25119797
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring for triazoles.
Hope WW; Billaud EM; Lestner J; Denning DW
Curr Opin Infect Dis; 2008 Dec; 21(6):580-6. PubMed ID: 18978525
[TBL] [Abstract][Full Text] [Related]
15. Development of an evaluation indicator system for the rational use of proton pump inhibitors in pediatric intensive care units: An application of Delphi method.
Ni X; Lin M; Li J; Zeng L; Li W; Huang L; Li D; Zhang L
Medicine (Baltimore); 2021 Jun; 100(24):e26327. PubMed ID: 34128875
[TBL] [Abstract][Full Text] [Related]
16. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.
van der Elst KC; Span LF; van Hateren K; Vermeulen KM; van der Werf TS; Greijdanus B; Kosterink JG; Uges DR; Alffenaar JW
Antimicrob Agents Chemother; 2013 Oct; 57(10):4999-5004. PubMed ID: 23896473
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
[TBL] [Abstract][Full Text] [Related]
18. Azole antifungals: 35 years of invasive fungal infection management.
Allen D; Wilson D; Drew R; Perfect J
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):787-98. PubMed ID: 25843556
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole in the treatment of invasive fungal infections.
Keady S; Thacker M
Intensive Crit Care Nurs; 2005 Dec; 21(6):370-3. PubMed ID: 15985371
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics of Triazoles in Pediatric Patients.
Bury D; Tissing WJE; Muilwijk EW; Wolfs TFW; Brüggemann RJ
Clin Pharmacokinet; 2021 Sep; 60(9):1103-1147. PubMed ID: 34002355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
